<DOC>
	<DOCNO>NCT00298467</DOCNO>
	<brief_summary>This study open-label , fixed-dose , multicenter study MDX-060 patient ALCL relapse refractory disease . There 3 phase study : Induction , Maintenance , Follow-up . Patients required attend protocol-required visit 4-week Induction Phase , administration MDX-060 occur , well test . Patients complete Induction Phase may eligible additional MDX-060 treatment ever 2 month 1 year Maintenance Phase . Patients complete Maintenance Phase response stable disease well follow every 2 month 1 year disease progression . The purpose study determine objective response rate Day 50 patient relapsed refractory classic systemic ALCL primary cutaneous ALCL treat MDX-060 . Other objective evaluate .</brief_summary>
	<brief_title>MDX-060 Patients With Relapsed Refractory Classic Systemic Primary Cutaneous Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description>This study open-label , fixed-dose , multicenter study MDX-060 patient ALCL relapse refractory disease . There 3 phase study : Induction , Maintenance , Follow-up . Patients required attend protocol-required visit 4-week Induction Phase , administration MDX-060 occur , well test . Patients complete Induction Phase may eligible additional MDX-060 treatment ever 2 month 1 year Maintenance Phase . Patients complete Maintenance Phase response stable disease well follow every 2 month 1 year disease progression . The primary objective study determine objective response rate ( ORR ) Day 50 patient relapsed refractory classic systemic anaplastic large cell lymphoma ( csALCL ) primary cutaneous ALCL ( pcALCL ) treat MDX-060 . The ORR base adaption NCI Response Criteria Non-Hodgkin 's Lymphoma ( NHL ) patient csALCL base Physician 's Global Assessment ( PGA ) patient pcALCL . Secondary objective include 1 ) characterize progression-free survival ( PFS ) ; 2 ) determine response duration ( RD ) ; 3 ) characterize effect MDX-060 health-related Quality Life ( QoL ) ; 4 ) evaluate patient pcALCL use adaption NCI Response Criteria NHL ; 5 ) characterize immunogenicity MDX-060 ; 6 ) characterize safety MDX-060 ; 7 ) determine best objective response rate ( BORR ) Maintenance Phase study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Lymphoma , Primary Cutaneous Anaplastic Large Cell</mesh_term>
	<criteria>sign informed consent confirm diagnosis ALCL patient csALCL must confirm CD30+ patient csALCL must fail relapse follow second line ( i.e . salvage ) chemotherapy relapse fail follow autologous stem cell transplant . patient pcALCL must progress treatment local radiation therapy surgical excision fail systemic therapy single agent multiagent regimen . patient pcALCL must confirm CD30+ ECOG performance 0 2 least 12 year age life expectancy 12 week great must meet screening laboratory value woman must postmenopausal least 1 year ; surgically incapable bearing child ; utilize reliable form contraception . All woman must negative pregnancy test . men must agree use male contraception duration study patient corticosteroid must taper medication 2 week prior first MDX060 administration remain corticosteroid day 365. previous treatment antiCD30 antibody history allogenic transplantation tumor lesion 10 cm great diameter malignancy , exclude basal squamous cell carcinoma skin , cervical carcinoma situ . Any cancer patient disease free least 5 year permissible . significant acter chronic infection . prior know serum positivity HIV , hepatitis B C determine screen . treatment investigational agent within 30 day 5 halflives ( whichever longer ) study screen . apparent active latent tuberculosis infection ( TB ) . patient pregnant nursing underlie medical condition , investigator 's opinion , make administration MDX060 hazardous obscure interpretation adverse event . concomitant chemotherapy , corticosteroid , investigational agent , antiALCL biologics , radiation therapy patient mycosis fungoides , patient recurrent , selfhealing papulonodular eruption lymphoma ALCL .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>ALCL</keyword>
	<keyword>csALCL</keyword>
	<keyword>pcALCL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Anaplastic Large Cell Lymphoma</keyword>
	<keyword>classic systemci Anaplastic Large Cell Lymphoma ( csALCL )</keyword>
	<keyword>primary cutaneous Anaplastic Large Cell Lymphoma ( pcALCL )</keyword>
</DOC>